跳至主要内容
临床试验/NCT02547038
NCT02547038已完成不适用

Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication

Kaohsiung Veterans General Hospital.1 个研究点 分布在 1 个国家目标入组 352 人开始时间: 2015年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
352
试验地点
1
主要终点
Number of Participants in Which H. Pylori Was Eradicated

研究概览

简要总结

Reverse hybrid therapy achieves a higher eradication rate than bismuth quadruple therapy remained unanswered.

详细描述

A 14-day hybrid therapy invented by our study group appears very promising in H. pylori eradication, achieving excellent eradication rates of 99% and 97% according to per-protocol and intention-to-treat analyses, respectively. Recently, the investigators demonstrated that the eradication rate of reverse hybrid therapy was higher than that of standard triple therapy. However, whether reverse hybrid therapy achieves a higher eradication rate than bismuth quadruple therapy remained unanswered.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
20 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis

排除标准

  • previous H pylori-eradication therapy
  • ingestion of antibiotics or bismuth within the prior 4 weeks
  • patients with allergic history to the medications used
  • patients with previous gastric surgery
  • the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
  • pregnant women

研究组 & 干预措施

pantoprazole+bismuth+tetra+metro

Experimental

pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days

干预措施: pantoprazole+bismuth+tetra+metro (Drug)

(panto+amox+clar+metr)+(panto+amox)

Active Comparator

a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily

干预措施: (panto+amox+clar+metr)+(panto+amox) (Drug)

结局指标

主要结局

Number of Participants in Which H. Pylori Was Eradicated

时间窗: sixth week after the end of anti- H. pylori therapy

Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ping-I (William) Hsu, M.D.

Professor

Kaohsiung Veterans General Hospital.

研究点 (1)

Loading locations...

相似试验